Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment
The following information on clinical trials is provided for information purposes only to
allow patients and physicians to have an initial discussion about the trial. This
information is not intended to be complete information about the trial, to contain all
considerations that may be relevant to potential participation in the trial, or to replace
the advice of a personal physician or health professional.
Main criteria are listed hereafter :
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
PSA decline
after each docetaxel administration and after the end of treatment
No
Zuzana MD Priborska
Study Director
Sanofi
Czech Republic: State Institute for Drug Control
XRP6976J_4001
NCT00280098
January 2006
Name | Location |
---|